Sanofi-Aventis, Regeneron extend development deal Nov 11, 2009
NEW YORK Sanofi-Aventis and Regeneron Pharmaceuticals Inc. said Tuesday they expanded an existing development partnership to run through 2017. Initially, the partnership signed in 2007 was set to end in 2012. (Yahoo News -- Pharmaceutical Industry News)
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued Sep 12, 2009
PARIS and TARRYTOWN, N.Y., Sept. 11 /PRNewswire-FirstCall/ -- Sanofi-aventis (Euronext: SAN and NYSE: ) and Regeneron Pharmaceuticals, Inc. (Nasdaq: ) today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC) ... About Regeneron Pharmaceuticals, Inc. ...... (PR Newswire)
Sanofi-Aventis could increase ophthalmology footprint with Allergan seen as strong candidate Aug 7, 2009
The person familiar with the situation noted Sanofis interest in ophthalmology with its stake in Regeneron Pharmaceuticals (NASDAQ:REGN). Bayer Healthcare, in turn, he said, has a notable partnership with Regeneron on the global development of VEGF Trap-Eye for the treatment of eye disease, including the neovascular form of wet age-related macular degeneration and diabetic eye diseases. (FT.com -- Markets)
Grand plan's quiet demise Jul 31, 2009
Regeneron Pharmaceuticals Inc. has its manufacturing plant adjacent to the campus. The new institute was to be jointly operated by the University at Albany and by Albany Medical Center. (Albany Times Union)
BioMed Realty Trust Reports Second Quarter 2009 Operating and Financial Results Jul 30, 2009
The company entered into 14 new leases totaling approximately 229,000 square feet, including a lease with Regeneron Pharmaceuticals, Inc. encompassing approximately 80,000 square feet at The Landmark at Eastview campus in Tarrytown, New York. Three leases totaling approximately 21,000 square feet were amended to extend their terms. (PR Newswire)
After Medarex buy, biotech investors ask who's next Jul 24, 2009
NEW YORK (Reuters) Investors bid up shares of Regeneron Pharmaceuticals Inc (REGN.O) and Seattle Genetics Inc (SGEN.O) on Thursday after Medarex Inc (MEDX.O) agreed to be acquired by Bristol-Myers Squibb Co (BMY.N) at a 90 percent premium. Analysts speculated that those two companies, which have similar specialties to Medarex, could be the next to be acquired. (Yahoo News -- Pharmaceutical Industry News)
BMY to buy Medarex for $2.4 bn Jul 23, 2009
Other companies that specialize in monoclonal antibodies include Regeneron Pharmaceuticals Inc, Seattle Genetics (SGEN.O), which has multiple collaborations, and Immunogen Inc.. Bristol-Myers said its purchase of Medarex has been unanimously approved by the boards of both companies and is expected to close in late August. (India Times)
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion Apr 30, 2009
BERLIN and TARRYTOWN, N.Y., April 30 /PRNewswire-FirstCall/ -- Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: ) today announced that the companies are extending their global development program for VEGF Trap-Eye, an investigational agent for the treatment of certain eye diseases, to include Central Retinal Vein Occlusion (CRVO) ... About Regeneron Pharmaceuticals ... Forward Looking Statement -- Regeneron Pharmaceuticals, Inc.. (PR Newswire)
Growth Factor TGF-B Helps Maintain Health Of Retinal Blood Vessels Apr 17, 2009
(June 18, 2003) Researchers at Johns Hopkins' Wilmer Eye Institute and Regeneron Pharmaceuticals have identified an experimental medicine that stops the blinding blood vessel growth associated with diabetic eye. (Mar. (Science Daily)
CEG tech awards honor Apkarian Apr 16, 2009
Economic Winner: Regeneron Pharmaceuticals. Technology in Production: Taconic Farms. (Albany Times Union)
